GeneDx price target raised to $105 from $80 at Jefferies on AAP update

Jefferies raised its price target on GeneDx (NASDAQ:WGS) to $105 from $80, maintaining a Buy rating, following a recent American Academy of Pediatrics (AAP) update that positively impacts the company's business outlook. The revised target, based on a discounted cash flow analysis, values GeneDx at 8 times its projected 2026 revenues, reflecting Jefferies' increased revenue forecasts for 2026 and 2027 and anticipation of significant multi-year tailwinds in the whole genome sequencing market.

Analysis

Jefferies has significantly increased its price target for GeneDx (WGS) to $105 from $80, reaffirming its Buy rating based on a new catalyst from the American Academy of Pediatrics (AAP). This update is perceived as a positive development for GeneDx's whole genome sequencing (WGS) business. The revised valuation stems from a discounted cash flow model that applies an 8x multiple to the company's projected 2026 revenues, a figure Jefferies justifies as being in line with both historical norms (6-9x) and the valuations of high-growth diagnostic peers (6-10x). In response to the AAP update, the firm has raised its revenue forecasts for GeneDx by 4% for 2026 and 3% for 2027, alongside upward revisions to long-term growth expectations. The core of the bullish thesis rests on the belief that GeneDx is positioned to capitalize on "multi-year tailwinds in an untapped market" with what Jefferies describes as "little to no competition," suggesting a strong competitive moat and a substantial growth runway.

Key Decisions for Investors

• Investors should consider the Jefferies upgrade as a strong validation of GeneDx's growth trajectory, especially given the new $105 price target is underpinned by a specific catalyst and revised, higher revenue forecasts for 2026 and beyond.
• The valuation multiple of 8x projected 2026 revenue, while aligned with peers, is a key assumption to monitor; continued execution and market adoption of WGS will be critical to sustaining this premium valuation.
• Given the analyst's emphasis on a lack of competition, it is crucial to monitor the diagnostics landscape for any emerging threats or alternative technologies that could challenge GeneDx's market position and the long-term growth thesis.